GleamWall
中文EN

CRIS CURIS INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1108205 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-36.9%
TTM net income YoY49.8%
TTM EPS YoY90.5%
Revenue 3-yr CAGR-12.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-100.2%
Net margin-299.7%
FCF margin—
EBITDA margin-98.5%

Returns

ROE-693.9%
ROA-61.3%
ROIC (approx.)—
Asset turnover0.20x

Leverage & solvency

Liabilities / assets57.2%
Debt / equity0.00x
Current ratio1.11x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.37x
Accruals ratio22.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$9.44M$10.91M
R&D expense$28.25M$38.56M
SG&A expense$14.05M$16.79M
Operating income-$5.71M-$44.54M
Income tax$0$0
Net income-$7.58M-$43.39M
EBITDA-$5.54M-$44.34M
EPS (basic)-0.58-6.88
EPS (diluted)-0.58-6.88
Weighted avg. shares (diluted)13.16M6.31M
Balance sheet
Cash & equivalents$5.06M$20.54M
Short-term investments—$0
Receivables$0$3.35M
Current assets$6.92M$26.39M
PP&E, net$62,000$231,000
Goodwill$8.98M$8.98M
Total assets$19.97M$41.27M
Current liabilities$14.08M$19.03M
Short-term debt$0$7.56M
Total liabilities$14.50M$47.26M
Shareholders' equity$5.46M-$6.00M
Shares outstanding646,5378.49M
Cash flow statement
Operating cash flow-$27.20M-$39.56M
Investing cash flow$2.50M$29.44M
Financing cash flow$9.77M$3.44M
Depreciation & amortization$169,000$203,000
Stock-based compensation$4.02M$5.93M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.